OctoPlus Strengthens its Senior Management Team

Jan 16, 2006, 00:00 ET from OctoPlus

    LEIDEN, The Netherlands, January 16 /PRNewswire/ -- OctoPlus, the drug
 delivery and development company, today announced two new appointments to its
 senior management team.
     Mr. Gerben Moolhuizen, MBA, previously Director OctoPlus Products, is
 promoted to Chief Business Officer and will join the company's senior
 management team. He replaces Dr. Henrik Luessen who is leaving to start his
 own consulting company, after seven years at OctoPlus.
     Gerben Moolhuizen joined the company in December 2001. Prior to joining
 OctoPlus he held business development positions at Primagen, Pharming and
 Eurocetus (now Chiron) where he gained more than 14 years of experience in
 successful deal making and obtaining venture capital financing for life
 science companies. Mr. Moolhuizen received his MBA from the Rotterdam School
 of Management and his M.Sc. in Medical Biology from Utrecht University.
     In addition, OctoPlus has recruited Dr. Ewoud van Hoogdalem to become
 Chief Medical Officer and a member of the management team. Ewoud van
 Hoogdalem was previously Director Experimental Medicine with Johnson &
 Johnson Pharmaceutical R&D based in Belgium. He brings to OctoPlus more than
 16 years of experience from Gist-Brocades (now DSM), Yamanouchi Europe and
 Johnson & Johnson, in clinical development from preclinical up to late
 clinical phases. Dr. Van Hoogdalem received his Ph.D. in Pharmacology and his
 M.Sc. in Pharmacy from Leiden University, and is a registered Clinical
     'We are pleased to welcome both Gerben and Ewoud to our senior team at
 this key time in OctoPlus' development' comments Dr. Joost Holthuis, CEO of
 OctoPlus. 'At the same time, we want to thank Dr. Luessen for his significant
 contributions and wish him every success with his own company.'
     About OctoPlus OctoPlus is a product-oriented drug delivery company that
 focuses on the development of innovative drug delivery systems to build a
 pipeline of product candidates. OctoPlus is also an internationally
 established provider of pharmaceutical development services and GMP
 manufacturing for pharmaceutical and biotechnology companies. The company is
 located in Leiden, the Netherlands.
     OctoPlus was founded in 1995 and currently employs more than 120 people.
 In January 2005 the company raised EUR 18 million in a second financing round
 from an international group of investors: Life Sciences Partners II B.V.
 (Amsterdam, the Netherlands), S.R. One, Ltd. (West Conshohocken, PA, USA),
 Innoven Partenaires (Paris, France), Fortis Private Equity (Brussels,
 Belgium) and SurModics, Inc. (Minneapolis, MN, USA).
     Website: www.octoplus.nl